News
Dr. Reddy's Laboratories Ltd. closed 16.71% below its 52-week high of 1,420.20 rupees, which the company reached on August ...
Dr. Reddy's Laboratories Ltd. closed 17.18% below its 52-week high of 1,420.20 rupees, which the company reached on August ...
Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing ...
Dr Reddys Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses ...
UltraTech Cement led the losses, with its share price falling by 2.47% to Rs 11,815.00. Dr Reddys Labs also saw a significant decrease, dropping 2.26% to Rs 1,171.60. Power Grid Corp's stock price ...
HYDERABAD: Dr Reddy’s Laboratories on Monday said it has expanded its strategic partnership with French biopharma giant ...
31 May, 2006 28 Aug, 2006 1:1 For every 1 share held; Holder will receive 1 bonus shares. 24 Mar, 1994 08 Apr, 1994 2:1 For every 1 share held; Holder will receive 2 bonus shares. 30 Sep, 1992 04 ...
5d
NDTV Profit on MSNDr Reddy's To Introduce Sanofi's Novel RSV Drug Beyfortus In IndiaUnder the arrangement, Dr Reddy's will have exclusive rights from Sanofi to promote and distribute Beyfortus in India.
SharkNinja, a global product design and technology company, has revealed the secret to happiness is closer to home than you think. In fact, its new research* suggests that the secret is your home. As ...
The logo, colors, and even SEBI license numbers look legit. The admins pose as me, Nikhil, Venu, or some of our employees. Step 2: Within hours, the chat is flooded with screenshots of 100–200% ...
In car rebadging partnerships, the original model developed by a manufacturer is sold to another company, which then uses its own brand logo on the vehicle and sells it in the market. There have ...
CuraTeQ Biologics s.r.o., announced that the CHMP of the European Medicines Agency has adopted a positive opinion recommending marketing authorisation of Dazublys®, its trastuzumab biosimilar, for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results